Yoshifumi Naka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshifumi Naka has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Mehmet C Oz
Department of Surgery, Division of Cardiothoracic Surgery, Columbia University, College of Physicians and Surgeons, New York, NY, USA
4 shared publicationsVivek Rao
Division of Cardiovascular Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada
4 shared publicationsHiroo Takayama
Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY
3 shared publicationsJonathan M. Chen
Division of Pediatric Cardiac Surgery , Weill Cornell University Medical Center, New York, NY , USA
3 shared publicationsMehmet C. Oz
From the Division of Cardiothoracic Surgery, Department of Surgery (M.J.R., J.M.C., K.N.H., A.S.S., M.A., M.C.O., Y.N.) and Division of Cardiology, Department of Medicine (D.D.A., D.M.M.), College of Physicians and Surgeons, and the International Center for Health Outcomes and Innovation Research (InCHOIR; M.J.R., D.D.A.); Columbia University New York, NY
3 shared publicationsMichael Argenziano
Division of Cardiothoracic Surgery, Columbia University, New York, NY
3 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Dominant intragraft plasma cells targeting bilirubin implicate local heme catabolism in human cardiac allograft vasculopathy
BACKGROUND: Cardiac allograft vasculopathy (CAV) is consistently accompanied by immune infiltrates surrounding affected coronary arteries, including antibody-producing plasma cells (PC). The antigenic drivers of these intragraft PC responses remain poorly defined. METHODS: We characterized graft infiltrating PC by single-cell RNA sequencing and immunoglobulin gene profiling. Using immunoglobulin sequences, we generated 37 recombinant monoclonal antibodies (mAb) from dominant intragraft PC clones and 24 control mAb from peripheral blood PC. Antigen reactivity was screened against chemical adducts, including bilirubin, a heme-degradation byproduct. Histologic and tissue analyses assessed bilirubin deposition as well as expression of hemecatabolic enzymes and the presence of Fe 2+ in heart explants with CAV. RESULTS: A majority of graft-derived mAb (21 of 37; approximately 57%) — but none of the mAb derived from blood PC — reacted to bilirubin. Bilirubin deposition was detected within lymphocytic aggregates in CAV grafts. In coronary arteries with CAV lesions, bilirubin accumulated in the cytoplasm and nuclei of smooth muscle cells in the tunica media, a pattern not observed in healthy heart tissue. Lastly, we detected the expression of heme-oxygenase-1 and biliverdin reductases in graft-infiltrating macrophages along with the presence of Fe 2+ ion in the media of arteries with hyperplasia. CONCLUSION: These findings suggest that local heme catabolism and resultant bilirubin accumulation create a prominent target for intragraft antibody responses in CAV. Bilirubin-specific antibodies and hemecatabolic pathways may contribute to CAV pathogenesis and represent potential mechanistic and therapeutic avenues for further investigation. FUNDING: Grants AI116814, AI154845, AI184963, and AI176507, HL148528, RYC2022-036797-I, P30CA013696, UL1TR001873, S10OD020056.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessDominant intragraft plasma cells targeting bilirubin implicate local heme catabolism in human cardiac allograft vasculopathy
BACKGROUND: Cardiac allograft vasculopathy (CAV) is consistently accompanied by immune infiltrates surrounding affected coronary arteries, including antibody-producing plasma cells (PC). The antigenic drivers of these intragraft PC responses remain poorly defined. METHODS: We characterized graft infiltrating PC by single-cell RNA sequencing and immunoglobulin gene profiling. Using immunoglobulin sequences, we generated 37 recombinant monoclonal antibodies (mAb) from dominant intragraft PC clones and 24 control mAb from peripheral blood PC. Antigen reactivity was screened against chemical adducts, including bilirubin, a heme-degradation byproduct. Histologic and tissue analyses assessed bilirubin deposition as well as expression of hemecatabolic enzymes and the presence of Fe 2+ in heart explants with CAV. RESULTS: A majority of graft-derived mAb (21 of 37; approximately 57%) — but none of the mAb derived from blood PC — reacted to bilirubin. Bilirubin deposition was detected within lymphocytic aggregates in CAV grafts. In coronary arteries with CAV lesions, bilirubin accumulated in the cytoplasm and nuclei of smooth muscle cells in the tunica media, a pattern not observed in healthy heart tissue. Lastly, we detected the expression of heme-oxygenase-1 and biliverdin reductases in graft-infiltrating macrophages along with the presence of Fe 2+ ion in the media of arteries with hyperplasia. CONCLUSION: These findings suggest that local heme catabolism and resultant bilirubin accumulation create a prominent target for intragraft antibody responses in CAV. Bilirubin-specific antibodies and hemecatabolic pathways may contribute to CAV pathogenesis and represent potential mechanistic and therapeutic avenues for further investigation. FUNDING: Grants AI116814, AI154845, AI184963, and AI176507, HL148528, RYC2022-036797-I, P30CA013696, UL1TR001873, S10OD020056.
- 1 February 2016
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 151 (2) , 520-527.e1
Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device
- 1 February 2016
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 151 (2) , 520-527.e1
Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device
- 19 October 2013
- Published by Springer Nature
- p. 97-111
Transplant Versus VAD: Evolving and Future Perspectives
- 19 October 2013
- Published by Springer Nature
- p. 97-111
Transplant Versus VAD: Evolving and Future Perspectives
- Open Access
- 1 February 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 12 (2) , 110-111
Implantation technique of the CentriMag biventricular assist device allowing ambulatory rehabilitation
Non-implantable ventricular assist device plays a major role in emergent or urgent situation where a patient has acutely decompensating hemodynamics.
- 1 February 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 12 (2) , 110-111
Open AccessImplantation technique of the CentriMag biventricular assist device allowing ambulatory rehabilitation
Non-implantable ventricular assist device plays a major role in emergent or urgent situation where a patient has acutely decompensating hemodynamics.
- Open Access
- 1 December 2009
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 138 (6) , 1425-1432.e3
Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices
- 1 December 2009
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 138 (6) , 1425-1432.e3
Open AccessPosttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices
- 21 November 2006
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (21) , 2280-2287
Survival After Heart Transplantation Is Not Diminished Among Recipients With Uncomplicated Diabetes Mellitus
Background— This study compares posttransplantation outcomes of survival and morbidity among recipients with and without diabetes mellitus (DM). Methods and Results— The United Network of Organ Sharing (UNOS) provided deidentified patient-level data. Primary analysis focused on 20 412 first-time heart transplant recipients aged ≥18 years who underwent transplantation between January 1, 1995, and December 31, 2005. To determine severity of DM, DM recipients were stratified by their aggregate number of diabetes-related complications (DRCs), including pretransplantation history of renal failure (serum creatinine=2.5 mg/dL), peripheral vascular disease, cerebrovascular accident, and severe obesity (body mass index ≥35 kg/m 2 ). Kaplan-Meier analysis was performed to compare time to event. Although posttransplantation survival was significantly better ( P P =0.08) between those without DM (10.1 years) and those with uncomplicated DM (0 DRCs; 9.3 years). Among those with DM, survival was worse with each additional DRC: 0 DRC, 9.3 years; 1 DRC, 6.7 years; and ≥2 DRCs, 3.6 years. Although acute rejection and transplant coronary artery disease–free survival did not differ between groups, renal failure and severe infection-free survival were worse in those with DM and were inversely related to the number of DRCs. Conclusions— Posttransplantation survival among patients with uncomplicated DM was not significantly different than that among nondiabetics. However, when stratified by disease severity, recipients with more severe diabetes had significantly worse survival than nondiabetics. Therefore, although DM alone should not be a contraindication to heart transplantation, given the critical shortage of transplantable organs, maximal benefit may be achieved by exploring alternative treatment options in patients with severe DM. These include use of high-risk transplant lists and destination therapy.
- 21 November 2006
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (21) , 2280-2287
Survival After Heart Transplantation Is Not Diminished Among Recipients With Uncomplicated Diabetes Mellitus
Background— This study compares posttransplantation outcomes of survival and morbidity among recipients with and without diabetes mellitus (DM). Methods and Results— The United Network of Organ Sharing (UNOS) provided deidentified patient-level data. Primary analysis focused on 20 412 first-time heart transplant recipients aged ≥18 years who underwent transplantation between January 1, 1995, and December 31, 2005. To determine severity of DM, DM recipients were stratified by their aggregate number of diabetes-related complications (DRCs), including pretransplantation history of renal failure (serum creatinine=2.5 mg/dL), peripheral vascular disease, cerebrovascular accident, and severe obesity (body mass index ≥35 kg/m 2 ). Kaplan-Meier analysis was performed to compare time to event. Although posttransplantation survival was significantly better ( P P =0.08) between those without DM (10.1 years) and those with uncomplicated DM (0 DRCs; 9.3 years). Among those with DM, survival was worse with each additional DRC: 0 DRC, 9.3 years; 1 DRC, 6.7 years; and ≥2 DRCs, 3.6 years. Although acute rejection and transplant coronary artery disease–free survival did not differ between groups, renal failure and severe infection-free survival were worse in those with DM and were inversely related to the number of DRCs. Conclusions— Posttransplantation survival among patients with uncomplicated DM was not significantly different than that among nondiabetics. However, when stratified by disease severity, recipients with more severe diabetes had significantly worse survival than nondiabetics. Therefore, although DM alone should not be a contraindication to heart transplantation, given the critical shortage of transplantable organs, maximal benefit may be achieved by exploring alternative treatment options in patients with severe DM. These include use of high-risk transplant lists and destination therapy.
- 1 February 2006
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 81 (2) , 642
Invited commentary
- 1 February 2006
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 81 (2) , 642
Invited commentary
- 1 November 2005
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 130 (5) , 1302-1309
Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation
- 1 November 2005
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 130 (5) , 1302-1309
Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation
- 12 July 2004
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 19 (4) , 361-366
Changing Trends in Mechanical Circulatory Assistance:. Experience With 131 Consecutive HeartMate VE Left Ventricular Assist Devices
Background: The success of long‐term implantable ventricular assist devices has led to their increased use in patients previously thought to be unsuitable for mechanical support. As a result, the demographic profile of patients presenting for LVAD support has changed over time. We reviewed our institutional experience to identify emerging risk factors and changing trends in patients who received the HeartMate VE LVAD. Methods: The clinical records were reviewed of 131 consecutive LVAD recipients between 1996 and 2001. All perioperative data were collected prospectively and entered into an institutional database. All patients received a preoperative risk stratification score based upon published criteria. The cohort was arbitrarily divided into early (n = 45), mid (n = 45), and late groups (n = 41). Results: Overall operative mortality was 25% with no difference between groups. The mean risk score increased significantly over time (early 3.5 ± 0.4 vs. late 5.3 ± 0.3, p < 0.05). The proportion of patients at high risk for mortality (score >5) was significantly higher in the late group (51% vs. 29%, p < 0.05). Although ventilation time and ICU stay was similar for all groups, hospital stay was longer in the late group (43 days vs. 23 days, p < 0.05). Mean duration of support fell from 90 to 59 days, but this failed to achieve statistical significance. Out‐patient therapy decreased from 73% in the early group to 15% in the late group (p < 0.001). Multivariate analysis identified right heart failure (odds ratio 4.1, 95% CI 2–11) and risk score (OR 1.4, 95% CI 1.2–1.6) as independent predictors of death. Conclusions: Despite an increasingly high risk patient population, the mortality associated with LVAD therapy has remained constant. Duration of LVAD support has decreased with a trend toward transplantation before hospital discharge. These data continue to support the aggressive institution of mechanical assistance for acute or chronic heart failure.
- 12 July 2004
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 19 (4) , 361-366
Changing Trends in Mechanical Circulatory Assistance:. Experience With 131 Consecutive HeartMate VE Left Ventricular Assist Devices
Background: The success of long‐term implantable ventricular assist devices has led to their increased use in patients previously thought to be unsuitable for mechanical support. As a result, the demographic profile of patients presenting for LVAD support has changed over time. We reviewed our institutional experience to identify emerging risk factors and changing trends in patients who received the HeartMate VE LVAD. Methods: The clinical records were reviewed of 131 consecutive LVAD recipients between 1996 and 2001. All perioperative data were collected prospectively and entered into an institutional database. All patients received a preoperative risk stratification score based upon published criteria. The cohort was arbitrarily divided into early (n = 45), mid (n = 45), and late groups (n = 41). Results: Overall operative mortality was 25% with no difference between groups. The mean risk score increased significantly over time (early 3.5 ± 0.4 vs. late 5.3 ± 0.3, p < 0.05). The proportion of patients at high risk for mortality (score >5) was significantly higher in the late group (51% vs. 29%, p < 0.05). Although ventilation time and ICU stay was similar for all groups, hospital stay was longer in the late group (43 days vs. 23 days, p < 0.05). Mean duration of support fell from 90 to 59 days, but this failed to achieve statistical significance. Out‐patient therapy decreased from 73% in the early group to 15% in the late group (p < 0.001). Multivariate analysis identified right heart failure (odds ratio 4.1, 95% CI 2–11) and risk score (OR 1.4, 95% CI 1.2–1.6) as independent predictors of death. Conclusions: Despite an increasingly high risk patient population, the mortality associated with LVAD therapy has remained constant. Duration of LVAD support has decreased with a trend toward transplantation before hospital discharge. These data continue to support the aggressive institution of mechanical assistance for acute or chronic heart failure.
- 31 May 2004
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 127 (5) , 1309-1316
Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience
- 31 May 2004
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 127 (5) , 1309-1316
Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience